ChinesepharmaceuticalcompanieslistedontheroadtoenlightenmentWestSideInrecentyears,pharmaceuticalcompaniestoenterthecapitalmarketbytheacceleratedpaceofpharmaceuticalhighIPOprice-earningsratioandotherfactors,drivenpharmaceuticalcompaniestoseekamorepositiveattitudetotheIPO,thecurrentstateisstilllistedinthequeueafew,ourlargepharmaceuticalcompaniestomorefrequentmergersoverallmarketdemand,fromwhichyoucandiscernthenextfiveyears,thedomesticpharmaceuticalindustrywillacceleratethereshuffle.Meanwhile,inChina’spharmaceuticalindustryaccountedformorethan90%ofSMEs,ifyouwanttostandup,youneedasquicklyaspossiblethroughthelistingtousethecapitalmarketbiggerandstronger.Onlyinthisway,theSMEmarketinordertorespondtofuturechangesinthepatterninthiscontext,China’spharmaceuticalmarketgrowingnumberofcases,thephenomenonwentoverseaslistingalsoincreasinglyprominent.Accordingtothecurrentsituation,thepharmaceuticalindustrypharmaceuticalmarketsituation---本文于网络，仅供参考，勿照抄，如有侵权请联系删除---andenvironmentisrelativelyfavorable.Pharmaceuticalindustryissupportedbythestateoftheindustry,withthecountry’snewmedicalreformpolicyDongfengforce,hasbeenpreparedforthepharmaceuticalcompanieslistedonasufficientcondition.Inaddition,asanon-cyclicalindustries,thepharmaceuticalindustryhasacertainabilitytoresistrisksagainstinflation.Moreover,thepharmaceuticalindustrybutalsoinstitutionsandanalystsagreethatthehighestdegreeofindustrysector,pharmaceuticalcompaniesoncelisted,themarketenvironmentisstillveryoptimistic.However,theterminationofthereviewoftheIPOonalistofcompanies,15pharmaceuticalcompaniesamongthem.Specifically,involvingthemotherboard,therearesevensmallplates,namelyCITICHealth,QuBOHAO,GuangdongPublichealth,ShanghaiBenjelloun,Heilong激angTianhong,HainanHuangLung,ChengduoldKen,involvingthepharmaceuticalcompaniestotheNorthoftheGEMWellman,Hainangasificationcombinedpharmaceutical,stateandmedicine,standatattentionup,Aetnabiological,Fu激anGuizhenChurch,GuiyangXintian,YiAnmedicalandothereightofwhichmAb---本文于网络，仅供参考，勿照抄，如有侵权请联系删除---leadingCITICHealthandFu激anGuizhenChurchonMay31thedayofself-examinationdeadlineare‘somereason’isdifficulttoissueaself-reportfromsuspendaudit‘Abortreview’IPOexitstatusischangedto‘End’state.Fromthis,thepharmaceuticalmarketstillfacesmanyproblemsandchallenges.Currently,IPOprocessrequiresmoreattentiontotheenterprisemarketlevel,profitmodelandoperatingnorms,especiallysoundfinancialsystemwhich,motherboardsandsmallplatesonthefinancialcapacityrequirementswouldbeparticularlystrict,therearemanycompaniesbecauseoffinancialverificationfoundsignificantproblemsandwithdrewtheapplicationmaterials,whiletheCommissionalsosaidthatthesecondfinancialself-examinationisaimedatisthroughthemorerigorousfinancialcheckstobelistedonthecompany’sfinancialsqueezedwater,tomaximizeitsperformancefaceandcurbfinancialfraud.Infact,recentIPOcomprehensivesituation,thefinancialsystemisnotuptothelistingofenterprisestendtobetwistsandturnsoftheroad,sopharmaceuticalcompanieswanttomarket,standardizeandimprovethefinancialsystemisahugechallenge.Inaddition,thecurrentIPOsystem---本文于网络，仅供参考，勿照抄，如有侵权请联系删除---othercontent,pharmaceuticalcompaniesalsoneedtobevigilantasIPOsystemforthecompany’sproductsisrequired,especiallyinthepharmaceuticalc...